Parents supportive of vaccinating boys for HPV

Vaccinemakers Merck ($MRK) and GlaxoSmithKline ($GSK) could boost revenues brought in by their HPV vaccines--Gardasil and Cervarix--if more boys received the shot regimen. A new study out of Boston University School of Medicine (BUSM) shows that more parents and guardians saw benefits than drawbacks to vaccinating boys. Researchers interviewed 120 parents and legal guardians of boys age 11 to 17 and found that more African-American (73%) and Latino (86%) than Caucasian (44%) participants supported school-entry mandates, but all felt that requirements should apply to both genders. "This study indicates that most parents would accept HPV vaccination for their sons just as readily as for daughters," Rebecca Perkins, assistant professor of obstetrics and gynecology at BUSM, said in a release. "Future research should explore the effects of the 2012 recommendations for routine vaccination for males on parental attitudes and uptake of HPV vaccination among both sexes." Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.